1
Total Mentions
1
Documents
0
Connected Entities
Organization referenced in documents
HOUSE_OVERSIGHT_024817_sub_001 - HOUSE_OVERSIGHT_024916
ffect sizes. Therefore, additional data from this and subsequent studies will be necessary to fully understand the potential of CBD in schizophrenia. GW Pharma has indicated that it intends to pursue CBD's future development in pediatric orphan neuropsychiatric indications. COWEN.COM HOUSE_OVERSIGHT_024908
No connected entities